TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 12 years of age.

REIMAGINE YOUR LIFE WITH HAE

I want to reimagine:

Reimagine your life with fewer attacks

People taking TAKHZYRO in a clinical study had attacks less often, and some people in the study had zero attacks.

In a 26-week clinical trial of 125 people with HAE 12 years of age and older, TAKHZYRO significantly reduced the number of monthly attacks, compared with placebo. People taking TAKHZYRO also had fewer moderate or severe attacks and fewer attacks requiring acute treatment, compared with placebo. And according to a supportive analysis, there were people taking TAKHZYRO who had zero attacks during the entire trial.

Has TAKHZYRO helped you?

WHAT IS TAKHZYRO?

TAKHZYRO is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older.

It is not known if TAKHZYRO is safe and effective in children under 12 years of age.

IMPORTANT SAFETY INFORMATION

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

wheezing

difficulty breathing

chest tightness

fast heartbeat

faintness

rash

hives

The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, and headache.

These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to the FDA at 1–800–FDA–1088.

TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

INTRODUCING TAKHZYRO™(lanadelumab-flyo)

WHAT IS TAKHZYRO?

TAKHZYRO (lanadelumab-flyo) is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older.

It is not known if TAKHZYRO is safe and effective in children under 12 years of age.

IMPORTANT SAFETY INFORMATION

TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:

wheezing

difficulty breathing

chest tightness

fast heartbeat

faintness

rash

hives

The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, and headache.

These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to the FDA at 1-800-FDA-1088.

TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.

SHARE YOUR STORY

If you’re a patient or caregiver interested in telling your story, we’d like to hear from you. Just click or tap “Yes” to continue.

HEADS UP!

You are now leaving TAKHZYRO.comBy clicking “Continue” below, you will be taken to a website that may contain links or references to other websites to which our Privacy Policy may not apply. We encourage you to read the privacy policy of every website you visit. By clicking the “No thanks” button below, you will be taken to the page you were on previously.